Milestone Pharmaceuticals' stock fell 50% after the FDA's CRL for CMC issues, but the drug Etripamil has shown efficacy and ...

Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...

Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of heart condition and had called for an inspection of the facility that ...

TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone ...

Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA.

Stock analysts at HC Wainwright lifted their Q1 2025 earnings estimates for Milestone Pharmaceuticals in a report issued on Tuesday, April 1st. HC Wainwright analyst P. Trucchio now anticipates that ...

In December 2023, Milestone Pharmaceuticals received an RTF letter from the FDA for insufficient TEAE data in their NDA filing, which precipitated a rapid decline in its share price. With an ...

H.C. Wainwright lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $10 from $25 and keeps a Buy rating on the shares after ...

MONTREAL and CHARLOTTE, N.C., March 13, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and full year ended ...

As for stock performance, Viking won there too in the early part of last year. The stock surged 121% in one trading session ...

Milestone Pharmaceuticals said on Friday that the U.S. health regulator had declined to approve its nasal spray to treat a ...